{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"16.85","value":"5.78"},{"groupId":"OG001","lowerLimit":"0.72","upperLimit":"18.07","value":"6.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Duration of CR was defined as the duration from date of first achieving CR to the date of disease progression (relapse) after CR, or death due to any cause. Participants last known to be alive who were free from disease progression or relapse after CR were censored at the date of the last assessment that verified their disease status. Duration of CR was analyzed using the Kaplan-Meier method. Disease progression was defined as: percentage of bone marrow blasts increased by ≥50% to \\>5% (for participants with \\<5% blasts at screening), \\>10% (for participants with 5-10% blasts at screening), \\>20% (for participants with 11-20% blasts at screening) or \\>30% (for participants with 21-30% blasts at screening), and with any of the following condition: at least 50% decrease from maximum remission/response in granulocytes or platelets; reduction in hemoglobin by ≥2 g/dL; transfusion dependence.","dispersionType":"Full Range","groups":[{"description":"Participants received SC or IV administration of azacitidine with a starting dose of 75 mg/m2/day for 7 days every 28 days, and received daily oral administration of glasdegib at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine with a starting dose of 75 mg/m2/day for 7 days every 28 days, and received daily oral administration of glasdegib at home with a starting dose of 100 mg QD.","id":"OG001","title":"MDS Cohort"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of 23 months in AML cohort and 34 months in MDS cohort","title":"Duration of CR in the AML and MDS Cohorts","type":"SECONDARY","unitOfMeasure":"Months"}